Bleomycin TACE for symptomatic giant nodular goiter
- 13 June 2026
- journal article
- Published by Springer Nature in European Radiology
- Vol. 36 (10) , 7651-7658
Abstract
Giant nodular goiters are hypervascular benign thyroid lesions whose surgical resection carries substantial risks. This study evaluates the feasibility, efficacy, and safety of transarterial chemoembolization (TACE) with bleomycin for symptomatic giant nodular goiter. This single-center retrospective study included patients with giant nodular goiter (≥ 4 cm) treated with TACE using 15,000 U bleomycin and 200-400 μm drug-loaded microspheres between May 2024 and May 2025. Primary outcomes were volumetric reduction and symptom relief. Secondary outcomes included complications and thyroid function changes. Non-parametric paired comparisons were used for statistical analysis. Fifty-one cases (mean age, 58 years [IQR, 42.75-64]) were evaluated. Technical success was achieved in all patients. Median goiter volume decreased from 192.7 cm³ (IQR, 125.4-350.1) to 70.45 cm³ (IQR, 54.04-102.1) at 6-month follow-up (p < 0.0001), representing a median volume reduction rate of 72.13% (IQR, 62.00-78.59). All patients achieved complete symptom remission by 1 month. No major procedure-related adverse events occurred. TACE with bleomycin is a safe and feasible minimally invasive option for symptomatic giant nodular goiter, achieving sustained volume reduction and complete symptom remission without major complications. Question Symptomatic giant nodular goiters pose substantial surgical risk; effective minimally invasive alternatives with durable volume reduction and symptom relief are lacking. Findings TACE with bleomycin-loaded microspheres achieved a median 72.13% volume reduction at 6 months with 100% symptomatic remission and no major complications in all patients. Clinical relevance TACE with bleomycin provides a safe, minimally invasive treatment option for patients with symptomatic giant nodular goiter who are unwilling or medically unfit for surgery, potentially reducing operative morbidity and improving quality of life.Keywords
Funding Information
- National Natural Science Foundation of China (82371962)
This publication has 22 references indexed in Scilit:
- Transarterial embolization outperforms radiofrequency ablation for thyroid goiters exceeding 100 mL: a study on efficacy and safetyEuropean Radiology, 2025
- Microwave ablation for benign thyroid nodules with cosmetic problems and related factors for post-ablative complete relief: a two-center retrospective studyEndocrine, 2024
- Long-Term Outcomes of Transarterial Chemoembolization of Giant Liver Hemangiomas with Lipiodol-Bleomycin EmulsionCardioVascular and Interventional Radiology, 2024
- Surgical Management of Substernal Thyroid GoitersOtolaryngologic Clinics of North America, 2023
- Thyroid Embolization for Nonsurgical Treatment of Nodular Goiter: A Single-Center Experience in 56 Consecutive PatientsJournal of Vascular and Interventional Radiology, 2021
- The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre studyClinical Radiology, 2021
- Bilateral patterns and motor function of the extralaryngeal branching of the recurrent laryngeal nerveSurgical and Radiologic Anatomy, 2018
- Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice CommitteeJournal of Vascular and Interventional Radiology, 2017
- Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goitersJournal of Endocrinological Investigation, 2015
- Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shuntsEuropean Radiology, 2009